LAST WEEK TODAY!

A summary of what was published on ProstateWarriors.com during the past week

Hi fellow warriors! This week we don’t have much to write about, but we believe the main reason is that we’ll have a lot of preliminary data coming from the AACR Annual Meeting, which will be held from April 25th to 30th! But as always, there’s still some interesting material this week. Stay strong and fight on!

As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE.​

Clinical Research

• FOR46 Demonstrates Encouraging Clinical Activity in Advanced Prostate Cancer​
  A Phase 1 clinical trial has yielded encouraging results for FOR46 (FG-3246), a novel antibody-drug conjugate developed to combat metastatic castration-resistant prostate cancer (mCRPC). The study indicated a manageable safety profile and significant clinical activityin patients who had exhausted conventional treatment options. Among patients treated at or above a certain dose, the median radiographic progression-free survival was 8.7 months, and some experienced disease control for nearly three years. Notably, 36% of patients had at least a 50% decline in PSA levels, and the objective response rate was 20%, signifying tumor shrinkage. The study also observed an increase in CD8+ T cells, suggesting a potential immune response.​
  ​
• China Approves Development of SKB107 for Bone Metastases​
  China’s National Medical Products Administration (NMPA) has approved the investigational new drug (IND) application for SKB107, a cutting-edge radionuclide-drug conjugate (RDC). This approval paves the way for clinical development of a potential breakthrough treatment for bone metastases. SKB107, known in early stages as TBM-001, represents a first-in-class therapy that combines a small molecule targeting ligand with conjugation technology, a chelator, and a therapeutic radionuclide to precisely attack cancer spread in the bone. Its targeted mechanism aims to limit damage to healthy tissue while aggressively eliminating cancerous cells in the bone. Phase 1 trial is set to begin soon.​
  ​

Preclinical Research

• New Radiotherapy ATNM-400 Targets Advanced Prostate Cancer with a Novel Approach​
  Actinium Pharmaceuticals has introduced ATNM-400, a pioneering radiotherapy utilizing Actinium-225 to treat advanced prostate cancer. Unlike traditional PSMA-targeting therapies, ATNM-400 employs a novel, non-PSMA targeting mechanism, potentially offering a treatment option for patients who do not respond to existing PSMA-based treatments. An impressive 99.8% tumor growth inhibition was achieved with a single dose of ATNM-400 in preclinical prostate cancer models. More precise preclinical data will be presented at AACR in April.
  ​
• Analysis of Second ARPI Use After Triplet Therapy Failure​
  Insights from the European Association of Urology (EAU) Annual Meeting 2025 explored the challenging clinical scenario of managing metastatic castration-resistant prostate cancer (mCRPC) progression after initial triplet therapyfor metastatic hormone-sensitive prostate cancer (mHSPC). The analysis considered whether a second androgen receptor pathway inhibitor (ARPI), such as abiraterone or enzalutamide, should be used after initial therapy fails. While generally responses to a second ARPI are limited, findings from the PSMAfore trial suggest that in carefully selected patients,particularly those initially treated with abiraterone, a temporary switch to a second ARPI might delay the need for more aggressive treatments. However, current clinical guidelines generally advise against routinely using a second ARPIupon progression due to limited effectiveness.
  ​
• AI-Guided Personalized Cancer Vaccines Show Early Promise in Clinical Application​
  A groundbreaking partnership is advancing personalized peptide vaccines designed using advanced artificial intelligence. These vaccines target the unique genetic makeup of each patient’s tumor. Early clinical application under a European compassionate use program has demonstrated striking results,including significant pain relief and meaningful improvements in quality of life for three patients with advanced bone metastases. Plans are underway for formal clinical trials in the United States to further evaluate this tailored immunotherapy approach. This initiative represents a shift towards precision medicine in cancer care.

And…that’s all folks! For today at least!
Please let me know if there is anything I can improve in my newsletters, and let me know if you have enjoyed the podcast.

If you this newsletter was delivered to your SPAM folder, make sure to let your email system know that it is not spam.
​
​
Have a great weekend!

Max